The article will build on another study published in the spring 2017 edition of Issues in Law and Medicine by his colleague Dr. Mary Davenport, which reviews studies on women who took mifepristone alone for abortion. The review, he said found the embryo survival rate to be between 8 and 25 percent.
Delgado said that upper limit of 25 percent will form the "historical control group" for comparing the embryo survival rates from their best progesterone-treatment protocols, which their data puts in the range of 60-70 percent.
"It does make a difference if a woman who changes her mind undergoes our reversal protocols," he said.
Many pro-life physicians and pro-life health centers across the country have now made abortion-pill reversal a treatment option to women.
Kathleen Eaton Bravo, founder of the Obria Medical Clinics and president of the Obria Foundation, told the National Catholic Register that Obria provides the progesterone treatment to women who request it. She said that as Obria's telemedicine platform expands in more states, it will provide another mechanism for women searching for help after taking the first abortion pill.
"We have a much better opportunity to save lives this way," she said. Bravo, who is a post-abortive mother, said when she had time to reflect on her surgical abortion decades ago, it was too late to do anything to save her child. But the woman who takes mifepristone in a doctor's office actually has time in the privacy of her home to consider whether she really wants to go through with abortion before taking the second pill. At that point, she said, a woman who changes her mind and wants to keep her baby will turn to her smartphone and start searching for help.
"We have a much larger window of opportunity to save this child's life if we can reach them through their smartphones," Bravo said. "This is a much bigger opportunity to save lives than we've ever had through surgical abortions."
Bravo said the best prevention against medication abortion is building relationships with abortion-vulnerable women so they never end up taking the abortion pill in the first place. She pointed out that Planned Parenthood's abortion business model today is based on pre-existing relationships with clients: It utilizes telemedicine to connect with women and men and is providing them with health services. She noted that in California, Planned Parenthood is expanding into primary care and is starting to rebrand as "Melody Women's Health."
Bravo said that Obria is seeking to build those pre-existing relationships with women and men by connecting to them through Obria's telemedicine platform and providing them with medical care and social support so that if they are in a crisis situation, they will turn to Obria first for help.
(Story continues below)
Subscribe to our daily newsletter
So far, just three states have enacted changes to informed-consent laws related to informing women about abortion reversal.
Arkansas explicitly requires women to be told that it might be possible to reverse a mifepristone abortion. South Dakota's legislation states that a woman does not have to continue the two-step abortion regimen if she changes her mind, and to look to the state health department's website for information on reversal – none of which can be found there. Arizona passed and then repealed legislation requiring women to be informed that medication abortion could be reversed after a court challenge.
Lawmakers in a handful of other states have attempted to bring similar bills to their statehouses for consideration based on model legislation developed by Americans United for Life (AUL).
Denise Burke, AUL's vice president of legal affairs, told the National Catholic Register that the organization believes women should know there's a "possibility" that they could increase their chances of keeping their children with this treatment.
"This is empowering women to make the best decision for them and their families," she said.
Burke said AUL has been in contact with a number of legislators that are contemplating bills for 2018. She hopes that the results of Delgado's forthcoming study will bolster the case for lawmakers for making this knowledge part of the informed-consent process for abortion.